Stock A032300 KOREA PHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials KOREA PHARMA Co., Ltd.

Equities

A032300

KR7032300006

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
19,240 KRW -0.31% Intraday chart for KOREA PHARMA Co., Ltd. +2.72% -18.65%
2023 Astrogen Co.,Ltd. announced that it has received KRW 2.999998662 billion in funding from KOREA PHARMA Co., Ltd. CI
2023 KOREA PHARMA Co., Ltd. announced that it has received KRW 23 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., EBEST Investment & Securities Co., Ltd. CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 242,129 529,520 233,403 257,943
Enterprise Value (EV) 1 237,216 520,707 224,952 244,495
P/E ratio 68.4 x 83.9 x -209 x 2,956 x
Yield - - - -
Capitalization / Revenue 3.39 x 6.65 x 2.88 x 3.1 x
EV / Revenue 3.32 x 6.54 x 2.78 x 2.94 x
EV / EBITDA 34.8 x 70.4 x 26.3 x 28.3 x
EV / FCF -50.8 x 519 x 161 x -144 x
FCF Yield -1.97% 0.19% 0.62% -0.69%
Price to Book 5.21 x 9.21 x 3.9 x 3.16 x
Nbr of stocks (in thousands) 10,907 10,907 10,907 10,907
Reference price 2 22,200 48,550 21,400 23,650
Announcement Date 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 71,510 79,577 81,029 83,240
EBITDA 1 6,824 7,391 8,567 8,653
EBIT 1 4,604 5,014 6,187 5,840
Operating Margin 6.44% 6.3% 7.64% 7.02%
Earnings before Tax (EBT) 1 3,768 5,208 -1,780 2,014
Net income 1 3,159 6,368 -1,119 83.76
Net margin 4.42% 8% -1.38% 0.1%
EPS 2 324.3 579.0 -102.6 8.000
Free Cash Flow 1 -4,674 1,004 1,395 -1,693
FCF margin -6.54% 1.26% 1.72% -2.03%
FCF Conversion (EBITDA) - 13.58% 16.29% -
FCF Conversion (Net income) - 15.76% - -
Dividend per Share - - - -
Announcement Date 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 4,913 8,813 8,451 13,449
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 -4,674 1,004 1,395 -1,693
ROE (net income / shareholders' equity) 8.64% 12.3% -1.91% 0.13%
ROA (Net income/ Total Assets) 3.89% 2.97% 2.97% 2.89%
Assets 1 81,288 214,112 -37,672 2,894
Book Value Per Share 2 4,264 5,269 5,484 7,485
Cash Flow per Share 2 1,546 5,184 769.0 4,521
Capex 1 1,974 2,552 2,465 1,531
Capex / Sales 2.76% 3.21% 3.04% 1.84%
Announcement Date 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
KOREA PHARMA CO., LTD. Stock KOREA PHARMA Co., Ltd.
-18.65% 155M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A032300 Stock
  4. Financials KOREA PHARMA Co., Ltd.